According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “
A number of other research firms have also issued reports on CMRX. HC Wainwright raised their target price on shares of Chimerix from $5.00 to $7.00 and gave the company a buy rating in a research note on Thursday, August 1st. ValuEngine upgraded shares of Chimerix from a sell rating to a hold rating in a research note on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $4.00.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.18). Chimerix had a negative net margin of 729.02% and a negative return on equity of 38.70%. The business had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.30 million. On average, research analysts expect that Chimerix will post -1.1 EPS for the current year.
A number of large investors have recently bought and sold shares of CMRX. SG Americas Securities LLC grew its stake in Chimerix by 105.4% in the 1st quarter. SG Americas Securities LLC now owns 20,590 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 10,567 shares during the last quarter. Quantitative Systematic Strategies LLC acquired a new position in Chimerix in the 2nd quarter valued at $67,000. Susquehanna International Group LLP acquired a new position in Chimerix in the 2nd quarter valued at $92,000. Prudential Financial Inc. acquired a new position in Chimerix in the 2nd quarter valued at $104,000. Finally, Marshall Wace LLP acquired a new position in Chimerix in the 1st quarter valued at $166,000. Institutional investors and hedge funds own 61.96% of the company’s stock.
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Read More: How to trade the most active stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.